Navigation Links
Ospedale Niguarda Ca' Granda-Milano Adopts Latest Technology to Treat Patients with Heart Failure
Date:8/5/2008

Orqis(R) Medical Reports Impressive Result in Hospitalized Patient

SCHAFFHAUSEN, Switzerland, Aug. 6 /PRNewswire/ -- Orqis(R) International GmbH, a medical products company marketing devices to treat heart failure, announced first use of the Cancion(R) System on May 27 by Dr. Maria Frigerio and Dr. Fabrizio Oliva at Ospedale Niguarda Ca' Granda-Milano, Milano, Italy, as part of the hospital's objective to provide the latest medical technology to treat patients.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080806/LAW519LOGO)

Dr. Frigerio and Dr. Oliva successfully treated a patient hospitalized with heart failure who was not responding to optimized medical management. Treatment with the Cancion System improved the patient's health to the point where the patient was successfully discharged home after being hospitalized for six months (since December 2007). Remarkably, he has remained out of the hospital over 65 days for any heart failure-related conditions.

The Cancion System enables aortic flow therapy which provides physicians with a low-risk tool to improve cardiac performance and unload the heart -- without touching the heart. The catheter-based, percutaneous device addresses patients suffering from acute decompensated heart failure by moving blood from an iliac artery to the descending aorta through the use of an extracorporeal circulatory support. This proprietary therapy uniquely bridges the treatment gap between medical management and more invasive procedures -- without ever touching the heart.

"There has been very little progress in creating effective new approaches for treating patients with heart failure," stated Dr. Frigerio. She continued, "The Cancion System provides Ospedale Niguarda Ca' Granda-Milano with the latest technology so we may provide the best care for our patients."

Laura Eaton, R.N., Director, U.S. Sales, Orqis Medical stated, "Use of the Cancion System in this patient demonstrates the compelling hemodynamic benefit of aortic flow therapy." She continued, "The Cancion System provides physicians with a viable new option to treat heart failure patients from a course of decline to a course of improvement."

The Cancion System is distributed in Italy by NGC Medical spa (http://www.ngc.it).

About Heart Failure

Heart failure is a condition in which the heart becomes weakened and cannot pump blood efficiently. Heart failure is caused by coronary artery disease, past myocardial infarctions, cardiomyopathy and other underlying cardiovascular disorders, and it is characterized by shortness of breath, functional impairment, and edema.

About Orqis International GmbH

Orqis is a privately held medical device company that develops and sells minimally invasive devices that improve cardiac performance through aortic flow therapy. Orqis devices uniquely bridge the treatment gap between medical management and more invasive procedures without ever touching the heart. The percutaneous Cancion System bears the CE mark of conformity, and the implantable Exeleras(R) System is in development.

For more information on Orqis Medical, please visit http://www.orqis.ch

Note: Orqis(R), Cancion(R), and Exeleras(R) are registered trademarks of Orqis Medical Corporation.


'/>"/>
SOURCE Orqis International GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AMA Adopts Strategies to Help Address Medical Student Debt
2. AMA Adopts New Public Health Policies at Annual Meeting
3. AMA Adopts New Policies at Annual Meeting
4. SyntheMed, Inc. Adopts Shareholder Rights Plan
5. Haemonetics Chairman and CEO Adopts 10b5-1 Stock Trading Plan
6. Virginias largest Cardiac Surgery program adopts SPY as standard of care
7. Edwards Lifesciences Chairman and CEO Adopts New 10b5-1 Stock Trading Plan to Replace Recently Expired Plan
8. Indiana Adopts Legislation to Combat Illegitimate Online Pharmacies, Protect Residents From Counterfeit Drugs
9. Weight Watchers COO Adopts 10b5-1 Trading Plan
10. Masimo Corporation Adopts Stockholder Rights Plan
11. APHA Adopts New Policies on Food Safety, Global Climate Change, Multidrug-Resistant Organisms, Breastfeeding and Feminine Hygiene
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... RICHEY, Fla. (PRWEB) , ... April 24, 2017 ... ... and Prevention (CDC), rising prescription opioid overdose deaths now claim the lives of ... slashed its civil case filings against drug manufacturers, distributors, pharmacies and prescribers by ...
(Date:4/24/2017)... ... April 24, 2017 , ... Pitavastatin, a relatively ... it is not known to have significant interactions with antiretroviral therapy (ART). ... cholesterol levels and dampen inflammation in the bloodstream. , While lowering cholesterol and ...
(Date:4/24/2017)... ... April 24, 2017 , ... Donna Parker, L. Ac. reads all sorts of ... of them to be very practical. She wanted to write a guide/workbook that would ... their health. It prompted her in writing “ A Clear Path to a Vibrant ...
(Date:4/24/2017)... ... April 24, 2017 , ... “The Saint with Trin, ... Trin, and Omega Station” is the creation of published author, Chris Jackson. Chris ... where he works in the Dallas Independent School District teaching English. He is heavily ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... of next generation neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke (AIS), ... ANCD BRAIN device as the product advances towards regulatory and clinical phases. , ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... Tenn. and DALLAS , April 19, 2017 ... announced that the first patients in Nashville ... device in the Lower Esophageal Sphincter Stimulation for GERD ... implantable device designed to provide long-term reflux control by ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
(Date:4/19/2017)... April 19, 2017  New research provides evidence that an ... according to a study released today that will be presented ... in Boston , April 22 to ... treatment of Parkinson,s disease, the oral drug levodopa has long ... longevity. But as the disease progresses, the effects of the ...
Breaking Medicine Technology: